Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Chantal Escot is active.

Publication


Featured researches published by Chantal Escot.


Oncogene | 1997

The proto-oncogene c- fos increases the sensitivity of keratinocytes to apoptosis

Valérie Mils; Jacques Piette; Caroline Barette; Jean-luc Veyrune; Anne Tesniere; Chantal Escot; Jean-Jacques Guilhou; Nicole Basset-Seguin

In human skin, most studies have suggested a role of c-fos or c-fos related genes in keratinocyte differentiation. The aim of our work was to more directly address this question by transfecting more or less differentiated keratinocyte cell lines (A431 and HaCaT) with constitutive expression vectors for c-Fos or c-Fos+c-Jun. Our results showed that c-Fos expression decreased keratinocyte growth, yet addition of c-Jun seemed to revert this c-Fos induced growth inhibition. Whereas no obvious differentiation program was turned on by c-Fos or c-Fos+c-Jun expression in our tissular model, apoptotic figures were observed and confirmed by in situ DNA fragmentation studies. These results do not rule out a role of c-Fos in keratinocyte differentiation but may indicate that the cell lines we used have reached an irreversible state of transformation so that they no longer respond to differentiation signals and rather die from apoptosis. These data add further evidence in favor of a role of c-Fos in epidermal homeostasis.


Breast Cancer Research and Treatment | 1996

Cellular localisation byin situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer

Chantal Escot; Yong Zhao; Carole Puech; Henri Rochefort

SummaryWe have compared by RNAin situ hybridisation on serial cryo-sections the distribution of cathepsin D (cath-D), stromelysin 3 (strom-3), and urokinase plasminogen activator (UPA) gene expression in different tissues of human benign and malignant mammary tumors. Cath-D expression was found to be higher in adenocarcinomas compared to non-tumoral glands. The cath-D RNA was located in mammary epithelial cancer cells rather than in fibroblasts, indicating that the cath-D gene was overexpressed in cancer cells, where the corresponding protein determined by immunohistochemical staining had been shown to be accumulated (P. Rogeret al., Human Pathol 25: 863–871, 1994). In contrast strom-3 RNA in adjacent tissue sections used as a control of tissue localisation was mostly expressed in peritumoral fibroblasts rather than in cancer cells confirming previous results of Bassetet al. and validating our methodology. UPA RNA was detected both in tumor cells and in stromal cells. In benign lesions the 3 protease RNAs were mostly found in epithelial cells. Stromal cells expressed UPA RNA in 5 of 7 lesions, cath-D and strom-3 in only one sample.We conclude that in breast cancer patients, cath-D gene expression is increased in epithelial mammary cancer cells at the RNA level as well as at the protein level, suggesting an altered transcriptional regulation. In non malignant lesions, the distribution was different with a predominant distribution in epithelial mammary cells for the 3 protease messenger RNA.


European Journal of Cancer | 1994

In vivo stimulation by tamoxifen of cathepsin D RNA level in breast cancer

Thierry Maudelonde; Chantal Escot; P. Pujol; P. Rouanet; Annick Defrenne; Jean-Paul Brouillet; Henri Rochefort

We have previously shown that 3 weeks of treatment with tamoxifen, of patients with primary breast carcinomas, increased cytosolic cathepsin D protein in oestrogen receptor (ER) positive tumours [Maudelonde et al., Cancer 1989, 63, 1265-1270]. In order to investigate the mechanism of this increase and to eliminate a transient flare-up effect, we semi-quantified cathepsin D RNA levels by in situ hybridisation in 32 breast carcinomas from patients treated with tamoxifen for 3 weeks prior to surgery and in 35 breast cancer patients receiving no tamoxifen. We found that tamoxifen increased cathepsin D RNA level regardless of the ER status of the tumours. In ER positive tumours, tamoxifen increased the cathepsin D RNA level to the same extent as cytosolic cathepsin D protein but not in ER negative tumours. The induction of cathepsin D RNA by tamoxifen in ER positive tumours was probably due to its agonist activity, also observed in vitro in breast cancer cell lines. These results suggest that the cathepsin D gene is inducible by oestrogens in ER positive breast cancer as it is in breast cancer cell lines.


Annals of the New York Academy of Sciences | 1990

Progestin-induced fatty acid synthetase in breast cancer : from molecular biology to clinical applications

Dany Chalbos; Christian Joyeux; Chantal Escot; Florence Galtier; Henri Rochefort

Progesterone and estrogens play an important role in the control of growth, differentiation, and function of mammary epithelial cells. Their mechanism of action can be studied in human metastatic breast cancer cell lines (e.g., MCF7, T47D, and ZR75-1) that contain progesterone and estrogen receptors.2 We used this system to try to define progestin-regulated human genes that would permit study of progestin regulation of gene expression in cell culture and to develop clinical markers of progestin responsiveness. This paper summarizes our investigation of the progestin-regulated 250K protein, recently identified as human fatty acid synthetase (FAS).


Proceedings of the National Academy of Sciences of the United States of America | 1986

Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas.

Chantal Escot; Charles Theillet; Rosette Lidereau; F Spyratos; Marie-Hélène Champème; Jean Gest; Robert Callahan


Cancer Research | 1986

Loss of a c-H-ras-1 Allele and Aggressive Human Primary Breast Carcinomas

Charles Theillet; Rosette Lidereau; Chantal Escot; Paula Hutzell; Maurice Brunet; Jean Gest; Jeffrey Schlom; Robert Callahan


Oncogene | 1989

Amplification of FGF-related genes in human tumors: possible involvement of HST in breast carcinomas.

Charles Theillet; Le Roy X; De Lapeyrière O; Grosgeorges J; Adnane J; Raynaud Sd; Joelle Simony-Lafontaine; Goldfarb M; Chantal Escot; Daniel Birnbaum


Laboratory Investigation | 1986

ras gene alterations and enhanced levels of ras p21 expression in a spectrum of benign and malignant human mammary tissues.

Thor A; Ohuchi N; Hand Ph; Robert Callahan; Weeks Mo; Charles Theillet; Rosette Lidereau; Chantal Escot; Page Dl; Vilasi


Mutation Research\/reviews in Genetic Toxicology | 1992

DNA amplification at 11q13 in human cancer: from complexity to perplexity

Patrick Gaudray; Pierre Szepetowski; Chantal Escot; Daniel Birnbaum; Charles Theillet


Cancer Research | 1988

In Situ c-myc Expression and Genomic Status of the c-myc Locus in Infiltrating Ductal Carcinomas of the Breast

Renato Mariani-Costantini; Chantal Escot; Charles Theillet; Annie Gentile; Giorgio R. Merlo; Rosette Lidereau; Robert Callahan

Collaboration


Dive into the Chantal Escot's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Robert Callahan

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Patrick Gaudray

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jean Marie Blanchard

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar

Guilhou Jj

University of Montpellier

View shared research outputs
Top Co-Authors

Avatar

Henri Pujol

University of Montpellier

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anne Tesniere

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar

Bernard Verrier

Centre national de la recherche scientifique

View shared research outputs
Researchain Logo
Decentralizing Knowledge